Safety and Efficacy of Human Clinical Trials Using Kidney-on-a-Chip Microphysiological Systems

We hypothesize that kidney-on-a-chip microphysiological systems (MPS) will manifest patient-specific phenotypic responses in vitro commensurate with clinical trial outcomes in vivo, establishing a robust molecular and cellular basis for kidney precision medicine approaches.